Inc. Hi, good morning everyone. So my name is Ying Huang. I'm the U.S. biotech analyst here and we are very pleased to have our next presenting biotech company which is Theravance. And Theravance has made a lot of progress recently in
Nano cap biotech Rexahn Pharmaceuticals ( RNN ) enjoys a pop in today's trading. Shares have eased a bit ..... Some observers perceive the action as proof of investors' overexuberance with all things biotech . Post your comment!
By DoctoRx : Background : The polymath entrepreneur Martine Rothblatt founded United Therapeutics ( UTHR ) after her daughter contracted pulmonary arterial hypertension (PAH), a disease that is usually fatal. UTHR succeeded in bringing several drug products to treat PAH to FDA approval; each has ...
By JMY Investments : This is our fourth article in a series of articles focused on early stage biotech companies in a race to treat incurable disease with the use of regenerative medicine. Our goal is to evaluate and compare the
Prana Biotechnology ( PRAN -2.2% ) is set to join the S&P/ASX 300 Index on March 21 following a quarterly review by Dow Jones. The S&P
By Scott Matusow : Many might not be familiar with who Randal J. Kirk is, but he is an influential man in the small cap biotech investment world. He got his start in business in the early 1980's and is now Chairman and Chief Executive Officer ( CEO
By Scrying Biotech : I'm a long-term investor and short-term trader of stocks. I don't buy or sell options, but were I too, I wouldn't
filing on Friday for a deal that could raise over $1 billion. It was one of 10 new filers, more than half of which were non- biotech health care companies. Only four such firms have gone public this year. Possible IPO trends now include health care and technology
Lombard Medical Technologies plans to delist in London and carry out an $80M IPO on Nasdaq, where it intends to trade under the ticker symbol " EVAR ." Lombard has yet to decide how many shares it will offer, nor at what price. The U.K. medical-devices company, which focus on the repair of ...
By Stephen Simpson, CFA : Biotech in general is still pretty hot, and orphan drugs development is hotter still. Even allowing for that background of bullishness